DBV Technologies grants CEO 1.74M PSUs tied to FDA acceptance of Viaskin Peanut BLAs

DBV Technologies S.A.

1,740,000 PSUs granted to CEO Daniel Tassé with grant date May 5, 2026.
50% vests upon FDA acceptance of BLA for ages 4-7; 50% for ages 1-3.
Vesting requires continued employment through July 1, 2028; shares delivered in four installments through Jan 2030.
If FDA accepts single BLA covering both age groups, all PSUs eligible to vest.
Unvested PSUs cancelled if milestones not achieved by July 1, 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.